Envisagenics
Leveraging artificial intelligence, high performance computing, and RNA sequencing data to find cures faster than ever before.
Launch date
Employees
Market cap
-
Enterprise valuation
$100—150m (Dealroom.co estimates Jun 2024.)
New York City New York (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$225k | Grant | ||
$225k | Grant | ||
N/A | N/A | Grant | |
$400k | Grant | ||
* | $2.4m | Seed | |
$1.5m | Grant | ||
$302k | Grant | ||
$300k | Grant | ||
N/A | N/A | Series A | |
N/A | Series A | ||
$1.0m | Grant | ||
* | $2.0m | Grant | |
N/A | N/A | Series A | |
* | $25.0m | Series B | |
Total Funding | $33.4m |
Related Content
Recent News about Envisagenics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.